BioCryst Pharmaceuticals BCRX Payments for finance leases
Payments for finance leases at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's payments for finance leases.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's payments for finance leases?
- BioCryst Pharmaceuticals (BCRX) reported payments for finance leases of $345K in Q1 2026.
- How has BioCryst Pharmaceuticals's payments for finance leases changed year-over-year?
- BioCryst Pharmaceuticals's payments for finance leases decreased by 33.1% year-over-year, from $516K to $345K.
- What does payments for finance leases mean?
- Principal payments on finance lease obligations, reducing the lease liability on the balance sheet.